AR082914A1 - Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos - Google Patents
Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismosInfo
- Publication number
- AR082914A1 AR082914A1 ARP110103259A ARP110103259A AR082914A1 AR 082914 A1 AR082914 A1 AR 082914A1 AR P110103259 A ARP110103259 A AR P110103259A AR P110103259 A ARP110103259 A AR P110103259A AR 082914 A1 AR082914 A1 AR 082914A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- lower alkyl
- group
- unsubstituted
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
A su obtención, a composiciones farmacéuticas que los contienen y a su utilización como medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes que elevan el nivel del colesterol HDL, por ejemplo en especial la dislipidemia, la aterosclerosis y las enfermedades cardiovasculares.Reivindicación 1: Compuestos de la fórmula (1) en la que: A1, A2 y A3 sé eligen entre N y CH, con la condición de que por lo menos uno de A1, A2 o A3 sea N y por lo menos uno de A1, A2 o A3 sea CH; R1 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, halógeno-alquilo inferior, carbamoilalquilo inferior, alquilcarbonilaminoalquilo inferior, fenilalquilo inferior, heterociclilalquilo inferior, cuyo resto heterociclilo está sin sustituir o sustituido por oxo, heteroarilalquilo inferior, cuyo resto heteroarilo está sin sustituir o mono- o disustituido por alquilo inferior y fenilo, que está sin sustituir o mono- o disustituido por halógeno; R2 y R6 con independencia entre sí son hidrógeno o halógeno; R3 y R5 con independencia entre sí se eligen entre el grupo formado por hidrógeno, alquilo inferior, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógenoalcoxi inferior y ciano; R4 se elige entre el grupo formado por hidrógeno, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógenoalcoxi inferior y ciano; o R4 y R5 junto con los átomos de C a los que están unidos forman un carbociclo de cinco o seis eslabones o un heterociclo de cinco o seis eslabones que contiene uno, dos o tres heteroátomos elegidos entre el grupo formado por N, O y S, dichos carbociclo o heterociclo están sin sustituir o sustituidos por uno o dos sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógeno-alcoxi inferior y ciano; R7 y R7’ con independencia entre sí son hidrógeno o alquilo inferior; R8 es un grupo heteroarilo de cinco o seis eslabones que contiene uno, dos o tres heteroátomos elegidos entre el grupo formado por N, O y S, dicho grupo heteroarilo está sin sustituir o sustituido por uno o dos sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, alcoxi inferior, halógeno, halógeno- alquilo inferior y cicloalquilo; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10175984 | 2010-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082914A1 true AR082914A1 (es) | 2013-01-16 |
Family
ID=44359517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103259A AR082914A1 (es) | 2010-09-09 | 2011-09-07 | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8729105B2 (es) |
| EP (1) | EP2613785B1 (es) |
| JP (1) | JP5667297B2 (es) |
| KR (1) | KR101546595B1 (es) |
| CN (1) | CN103118680B (es) |
| AR (1) | AR082914A1 (es) |
| BR (1) | BR112013005622A2 (es) |
| CA (1) | CA2808665A1 (es) |
| ES (1) | ES2548035T3 (es) |
| HK (1) | HK1181655A1 (es) |
| MX (1) | MX2013002660A (es) |
| RU (1) | RU2013113118A (es) |
| TW (1) | TW201217367A (es) |
| WO (2) | WO2012031817A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| TWI644016B (zh) * | 2012-11-02 | 2018-12-11 | 艾克頌美孚上游研究公司 | 用於在化學計量廢氣再循環氣渦輪系統中以氧化劑－稀釋劑混合進行擴散燃燒之系統及方法 |
| LT2928882T (lt) | 2012-12-07 | 2017-03-27 | F. Hoffmann-La Roche Ag | Pirazino dariniai kaip cb2 receptoriaus agonistai |
| LT2928868T (lt) * | 2012-12-07 | 2017-10-25 | F. Hoffmann-La Roche Ag | Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai |
| WO2014086705A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
| MY179412A (en) | 2012-12-07 | 2020-11-05 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| PE20161407A1 (es) * | 2014-04-04 | 2016-12-28 | Hoffmann La Roche | Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide |
| SG11201608108SA (en) * | 2014-04-04 | 2016-10-28 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
| WO2018234284A1 (en) * | 2017-06-20 | 2018-12-27 | F. Hoffmann-La Roche Ag | PYRIDINE DERIVATIVES |
| US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| EP4096656A4 (en) * | 2020-02-02 | 2023-07-12 | Ramot at Tel-Aviv University Ltd. | NOVEL ACTIVATORS OF ATP-BINDING CASSETTE PROTEIN TYPE 1 (ABCA1) AND THERAPEUTIC USES THEREOF |
| CN113390984B (zh) * | 2021-05-31 | 2022-09-16 | 常州沃腾化工科技有限公司 | 环丁醇和环丙甲醇的气相分离分析方法 |
| US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| SE0104332D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| WO2006106054A1 (en) * | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| ES2344128T3 (es) * | 2006-10-04 | 2010-08-18 | F. Hoffmann-La Roche Ag | Derivados de pirazina-2-carboxamida como moduladores de receptores cb2. |
| BRPI0717845A2 (pt) * | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
| US7897621B2 (en) | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
| US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| WO2010051188A1 (en) * | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| US8669254B2 (en) * | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
-
2011
- 2011-07-21 WO PCT/EP2011/062548 patent/WO2012031817A1/en active Application Filing
- 2011-09-06 RU RU2013113118/04A patent/RU2013113118A/ru not_active Application Discontinuation
- 2011-09-06 WO PCT/EP2011/065341 patent/WO2012032018A1/en active Application Filing
- 2011-09-06 BR BR112013005622A patent/BR112013005622A2/pt not_active IP Right Cessation
- 2011-09-06 KR KR1020137008925A patent/KR101546595B1/ko not_active IP Right Cessation
- 2011-09-06 EP EP11752233.4A patent/EP2613785B1/en not_active Not-in-force
- 2011-09-06 CN CN201180043044.7A patent/CN103118680B/zh not_active Expired - Fee Related
- 2011-09-06 JP JP2013527569A patent/JP5667297B2/ja not_active Expired - Fee Related
- 2011-09-06 ES ES11752233.4T patent/ES2548035T3/es active Active
- 2011-09-06 CA CA2808665A patent/CA2808665A1/en not_active Abandoned
- 2011-09-06 MX MX2013002660A patent/MX2013002660A/es active IP Right Grant
- 2011-09-07 TW TW100132315A patent/TW201217367A/zh unknown
- 2011-09-07 AR ARP110103259A patent/AR082914A1/es not_active Application Discontinuation
- 2011-09-07 US US13/226,521 patent/US8729105B2/en not_active Expired - Fee Related
-
2013
- 2013-08-01 HK HK13108974.8A patent/HK1181655A1/zh not_active IP Right Cessation
-
2014
- 2014-02-24 US US14/187,723 patent/US9090599B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130081288A (ko) | 2013-07-16 |
| JP5667297B2 (ja) | 2015-02-12 |
| EP2613785A1 (en) | 2013-07-17 |
| US9090599B2 (en) | 2015-07-28 |
| TW201217367A (en) | 2012-05-01 |
| BR112013005622A2 (pt) | 2016-05-03 |
| WO2012032018A1 (en) | 2012-03-15 |
| CN103118680A (zh) | 2013-05-22 |
| CA2808665A1 (en) | 2012-03-15 |
| KR101546595B1 (ko) | 2015-08-21 |
| CN103118680B (zh) | 2015-12-16 |
| MX2013002660A (es) | 2013-04-09 |
| EP2613785B1 (en) | 2015-07-29 |
| US20120065212A1 (en) | 2012-03-15 |
| JP2013537173A (ja) | 2013-09-30 |
| ES2548035T3 (es) | 2015-10-13 |
| US8729105B2 (en) | 2014-05-20 |
| US20140194436A1 (en) | 2014-07-10 |
| HK1181655A1 (zh) | 2013-11-15 |
| WO2012031817A1 (en) | 2012-03-15 |
| RU2013113118A (ru) | 2014-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098492A1 (es) | Derivados de purina | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |